The National Kidney Foundation (NKF) is proud to announce that its KidneyCARE (Community Access to Research Equity)™ Study – ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one ...

By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the ...

Dr Andrew Bomback comments on how disparities in access to healthcare significantly delay the diagnosis and treatment of IgA ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Immunoglobulin A (IgA) nephropathy, also called Berger’s disease, is an autoimmune disease that affects your kidneys. IgA is an antibody. Antibodies are proteins made by your immune system.

Dr Andrew Bomback reflects on how IgA nephropathy treatment has evolved from limited options like prednisone to a growing arsenal of targeted therapies.

The disease affects around 130,000 people in the US and another 115,000 in Europe. The new results from the phase 1b/2a RUBY study in 41 IgAN patients showed that povetacicept given by ...

aimed at treating IgA nephropathy (IgAN), a kidney disease. The Phase 1/2 study demonstrated significant reductions in key markers of disease activity and proteinuria, a sign of kidney damage.